WO2009060473A3 - Injectable compositions, processes and uses thereof - Google Patents
Injectable compositions, processes and uses thereof Download PDFInfo
- Publication number
- WO2009060473A3 WO2009060473A3 PCT/IN2008/000757 IN2008000757W WO2009060473A3 WO 2009060473 A3 WO2009060473 A3 WO 2009060473A3 IN 2008000757 W IN2008000757 W IN 2008000757W WO 2009060473 A3 WO2009060473 A3 WO 2009060473A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- pharmaceutically acceptable
- processes
- injectable compositions
- biocompatible
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Abstract
Injectable depot gel or implant compositions comprising at least one active agent(s) selected from a group comprising antipsychotics, aromatase inhibitors, alpha-1 adrenergic blocking agents, acetylcholinesterase inhibitors, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s) are provided. The present invention also describes process for preparation of such compositions and method of using such compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2321DE2007 | 2007-11-06 | ||
IN2321/DEL/2007 | 2007-11-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009060473A2 WO2009060473A2 (en) | 2009-05-14 |
WO2009060473A3 true WO2009060473A3 (en) | 2009-10-15 |
Family
ID=40626309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2008/000757 WO2009060473A2 (en) | 2007-11-06 | 2008-11-06 | Injectable compositions, processes and uses thereof |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR070033A1 (en) |
CL (1) | CL2008003305A1 (en) |
WO (1) | WO2009060473A2 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8110209B2 (en) | 2002-12-20 | 2012-02-07 | Xeris Pharmaceuticals Inc. | Intracutaneous injection |
US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
ES2390439B1 (en) * | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | INJECTABLE COMPOSITION |
US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
ES2589106T3 (en) * | 2010-05-31 | 2016-11-10 | Laboratorios Farmaceuticos Rovi, S.A. | Injection controlled antipsychotic composition |
US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
HUE057236T2 (en) * | 2010-05-31 | 2022-04-28 | Farm Rovi Lab Sa | Compositions for injectable in-situ biodegradable implants |
US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
WO2012012460A1 (en) | 2010-07-19 | 2012-01-26 | Xeris Pharmaceuticals, Inc. | Stable glucagon formulations for the treatment of hypoglycemia |
US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
MX339196B (en) * | 2010-10-28 | 2016-05-16 | Aequus Pharmaceuticals Inc | Aripiprazole compositions and methods for its transdermal delivery. |
MA34832B1 (en) | 2010-12-29 | 2014-01-02 | Medincell | BIODEGRADABLE DRUG DELIVERY COMPOSITIONS |
MX342675B (en) | 2011-03-10 | 2016-10-07 | Xeris Pharmaceuticals Inc | Stable formulations for parenteral injection of peptide drugs. |
HUE032109T2 (en) | 2011-03-18 | 2017-08-28 | Alkermes Pharma Ireland Ltd | Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20 |
US8980298B2 (en) | 2011-10-24 | 2015-03-17 | Braeburn Pharmaceuticals Bvba Sprl | Implantable tizanidine compositions and methods of treatment thereof |
KR20140103927A (en) * | 2011-10-24 | 2014-08-27 | 엔도 파마슈티컬즈, 솔루션스 아이엔씨. | Implantable drug delivery compositions and methods of treatment thereof |
EA027744B1 (en) | 2011-10-31 | 2017-08-31 | Ксерис Фармасьютикалс, Инк. | Formulations for the treatment of diabetes mellitus |
EP2827868B8 (en) | 2012-03-19 | 2019-12-18 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
NZ630428A (en) * | 2012-03-19 | 2017-02-24 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising benzyl alcohol |
JP6219918B2 (en) * | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | Pharmaceutical composition comprising glycerol ester |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
EP3718536A1 (en) | 2012-09-19 | 2020-10-07 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
US20160022571A1 (en) * | 2013-03-14 | 2016-01-28 | Braeburn Pharmaceuticals Bvba Sprl | Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof |
MA39495A (en) | 2014-03-20 | 2015-09-24 | Alkermes Pharma Ireland Ltd | ARIIPIPRAZOLE FORMULATIONS WITH HIGHER INJECTION RATES |
CN106573106B (en) | 2014-08-06 | 2021-06-22 | Xeris药物公司 | Syringe, kit and method for intradermal and/or subcutaneous injection of a paste |
CN104189954B (en) * | 2014-09-19 | 2017-03-29 | 中国科学院长春应用化学研究所 | A kind of in-situ solidifying tissue engineering bracket and preparation method thereof |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
CA2994704A1 (en) * | 2015-08-03 | 2017-02-09 | Tolmar International Limited | Liquid polymer delivery system for extended administration of drugs |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
AU2016355236C1 (en) | 2015-11-16 | 2022-09-22 | Medincell | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
WO2018015915A1 (en) | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
KR102033686B1 (en) * | 2017-05-19 | 2019-10-18 | 보령제약 주식회사 | Microneedle transdermal patch comprising donepezil |
AU2018275686B2 (en) | 2017-06-02 | 2024-02-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
GB2568526A (en) * | 2017-11-20 | 2019-05-22 | Rebio Tech Oy | Composition |
CN112423754A (en) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | Aripiprazole administration strategy |
PE20210047A1 (en) * | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | INJECTABLE COMPOSITION |
AR116501A1 (en) * | 2018-09-25 | 2021-05-12 | Tolmar Int Ltd | LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED DRUG ADMINISTRATION |
US11911499B2 (en) * | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
CN113209370B (en) * | 2020-01-21 | 2023-11-28 | 渼颜空间(河北)生物科技有限公司 | Biodegradable injection filler, preparation method and application thereof |
EP4362932A1 (en) * | 2021-06-30 | 2024-05-08 | The University of North Carolina at Chapel Hill | Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery |
WO2023116517A1 (en) * | 2021-12-24 | 2023-06-29 | 四川科伦药物研究院有限公司 | Continuous delivery preparation capable of being stably released and preparation method therefor |
US11602516B1 (en) | 2022-01-29 | 2023-03-14 | Resurge Therapeutics Inc. | Treating benign prostatic hyperplasia |
US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0950403A2 (en) * | 1998-04-14 | 1999-10-20 | Atrix Laboratories, Inc. | Emulsions for in-situ delivery systems |
WO2000024374A1 (en) * | 1998-10-28 | 2000-05-04 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6331311B1 (en) * | 1996-12-20 | 2001-12-18 | Alza Corporation | Injectable depot gel composition and method of preparing the composition |
WO2002049573A2 (en) * | 2000-12-18 | 2002-06-27 | Wockhardt Limited | Novel in-situ forming controlled release microcarrier delivery system |
WO2006053175A2 (en) * | 2004-11-10 | 2006-05-18 | Qlt Usa Inc. | A stabilized polymeric delivery system |
WO2007026145A1 (en) * | 2005-08-31 | 2007-03-08 | Astrazeneca Ab | Prolonged release formulations comprising anastrozole |
WO2008041245A2 (en) * | 2006-10-05 | 2008-04-10 | Panacea Biotec Ltd. | Injectable depot composition and it's process of preparation |
-
2008
- 2008-11-06 AR ARP080104860A patent/AR070033A1/en unknown
- 2008-11-06 CL CL2008003305A patent/CL2008003305A1/en unknown
- 2008-11-06 WO PCT/IN2008/000757 patent/WO2009060473A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6331311B1 (en) * | 1996-12-20 | 2001-12-18 | Alza Corporation | Injectable depot gel composition and method of preparing the composition |
EP0950403A2 (en) * | 1998-04-14 | 1999-10-20 | Atrix Laboratories, Inc. | Emulsions for in-situ delivery systems |
WO2000024374A1 (en) * | 1998-10-28 | 2000-05-04 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
WO2002049573A2 (en) * | 2000-12-18 | 2002-06-27 | Wockhardt Limited | Novel in-situ forming controlled release microcarrier delivery system |
WO2006053175A2 (en) * | 2004-11-10 | 2006-05-18 | Qlt Usa Inc. | A stabilized polymeric delivery system |
WO2007026145A1 (en) * | 2005-08-31 | 2007-03-08 | Astrazeneca Ab | Prolonged release formulations comprising anastrozole |
WO2008041245A2 (en) * | 2006-10-05 | 2008-04-10 | Panacea Biotec Ltd. | Injectable depot composition and it's process of preparation |
Also Published As
Publication number | Publication date |
---|---|
AR070033A1 (en) | 2010-03-10 |
WO2009060473A2 (en) | 2009-05-14 |
CL2008003305A1 (en) | 2009-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009060473A3 (en) | Injectable compositions, processes and uses thereof | |
WO2003062248A3 (en) | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists | |
WO2010026436A3 (en) | 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders | |
WO2003073986A3 (en) | Aminoalkylphosphonates and related compounds as edg receptor agonists | |
WO2007027527A3 (en) | Isoindole-imide compounds and compositions comprising and methods of using the same | |
WO2007002313A3 (en) | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | |
UA94964C2 (en) | 5-substituted quinazolinone derivatives, composition containing thereof and use thereof | |
NO20076288L (en) | Pharmaceutical compositions including imatinib and a release-lowering agent | |
WO2007002635A3 (en) | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
MX2009012847A (en) | Dipeptide analogs as coagulation factor inhibitors. | |
WO2004112710A3 (en) | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß | |
WO2004058149A3 (en) | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles | |
TNSN07490A1 (en) | Pharmaceutical sustained release compositions and processes thereof | |
WO2008048981A3 (en) | Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
WO2020257549A3 (en) | Compounds for treatment of pd-l1 diseases | |
HK1120506A1 (en) | Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4) | |
WO2011003018A3 (en) | Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof | |
WO2003074008A3 (en) | Aminoalkylphosphonates and related compounds as edg receptor agonists | |
WO2005032465A3 (en) | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists | |
WO2007032028A8 (en) | Thiazolinones and oxazolinones and their use as ptp1b inhibitors | |
WO2005105088A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension | |
WO2005094810A3 (en) | Novel pharmaceutical compositions | |
WO2008157751A3 (en) | Substituted imidazoheterocycles | |
IN2014KN02886A (en) | ||
WO2004066965A3 (en) | Method of preventing surgical adhesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08846791 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08846791 Country of ref document: EP Kind code of ref document: A2 |